Repligen Corporation, a leading biopharma manufacturing company, has once again exceeded expectations with its outstanding performance in Q2 CY2025. With a remarkable 17% organic non-COVID growth, the company’s President and CEO, Olivier Loeillot, expressed satisfaction with the momentum seen across the portfolio. Repligen’s success in both consumables and capital equipment, coupled with strong biopharma demand, has contributed to its continuous growth. Orders have surged by over 20%, marking the eighth consecutive quarter of orders surpassing non-COVID revenue and the fifth quarter of sequential order growth. This achievement is a testament to Repligen’s differentiated strategy, resulting in a commendable 15% organic non-COVID growth in the first half of 2025.
With a history of strategic acquisitions since 2012, Repligen has built a robust bioprocessing portfolio, developing specialized technologies that enhance the efficiency and flexibility of biological drug manufacturing processes. The company’s long-term sales performance reflects its commitment to growth, with an impressive 17.4% annualized revenue growth over the last five years, surpassing the industry average and indicating strong customer resonance.
Repligen’s Q2 CY2025 results have surpassed Wall Street’s revenue expectations, with sales increasing by 14.8% year-on-year to reach $182.4 million. The company’s full-year revenue guidance of $725 million at the midpoint exceeded analysts’ estimates by 2.1%. Additionally, Repligen reported an adjusted EBITDA of $32.18 million, surpassing analyst estimates by 2.5%. Management has raised its revenue guidance for the full year, demonstrating confidence in the company’s continued growth trajectory.
For more insights on Repligen’s impressive performance and strategic outlook, visit finance.yahoo.com.
Read more from finance.yahoo.com